
SpliSense Advances Phase 2b Trial for Cystic Fibrosis Therapy SPL84
Patients carrying the 3849+10kb C→T CFTR mutation will serve as the focus for a new Phase 2b clinical trial, as Jerusalem-based SpliSense evaluates its inhaled antisense oligonucleotide, SPL84, as an add-on therapy for those already stabilized on standard CFTR modulator treatments.

























